Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment

Clinical Infectious Diseases

Volumn 26, Issue 5, 1998, Pages 1233-

  Hammoud, Zena ^a   Parenti, David M ^a   Simon, Gary L ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0031902823     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598351     Document Type: Article

References (5)

1. Moore P, Change Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma lesions from persons with and without HIV infection. N Engl J Med 1995;332:1181-5.
2. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 1997;99:2082-6.
3. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996;173:1477-80.
4. Costagliola D, Mary-Krause M. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficience Humaine [letter]. Lancet 1995; 346:578.
5. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994; 26:749-52.